We could not find any results for:
Make sure your spelling is correct or try broadening your search.
IPA's Subsidiary BioStrand Secures Second VLAIO Research GrantIPA subsidiary BioStrand receives grant to expand LENSai platform by linking HYFTs™ with 3D protein structure and...
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and...
IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence New Platform...
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of...
IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 In vivo, IND enabling evaluations of PolyTope® TATX-03 in animal model show:There were no...
Traitement potentiel de la maladie de Parkinson et d'autres affections neurodégénératives IMMUNOPRECISE ANTIBODIES LTD. (la "Société" ou "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) un chef de file...
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease Potential to Treat Parkinson's and Other...
Potential to Treat Parkinson’s and Other Neurodegenerative Diseases IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic...
L'anticorps bloque l'interaction de liaison DFR/ACE2 par le biais d'un mécanisme d'action alternatif L'anticorps se lie à tous les variants préoccupants testés, probablement parce qu'il cible un...
Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action Binds to all tested variants of concern, likely because it targets a site other than the mutation...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 6.5 | 6.5 | 6.5 | 0 | 0 | CS |
4 | 0 | 0 | 6.5 | 6.5 | 6.5 | 0 | 0 | CS |
12 | 0 | 0 | 6.5 | 6.5 | 6.5 | 0 | 0 | CS |
26 | 0 | 0 | 6.5 | 6.5 | 6.5 | 0 | 0 | CS |
52 | 0 | 0 | 6.5 | 6.5 | 6.5 | 0 | 0 | CS |
156 | -0.49 | -7.01001430615 | 6.99 | 8.44 | 4.52 | 6237 | 6.39434673 | CS |
260 | 5.98 | 1150 | 0.52 | 26.25 | 0.5 | 74071 | 4.03017394 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions